La chaîne d'options affiche les données clés des options sur actions de PureTech Health à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour PureTech Health..

PureTech Health (NASDAQ:PRTC) Stock, Chaîne d'Options

PureTech Health

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

PureTech Health plc - American Depositary Shares

PureTech Health PLC

JP Morgan analyst Kenneth Worthington maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and lowers the price target from $15 to $14.5.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on P10, Lowers Price Target to $14.5

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly earnings of $2.56 per share which beat the analyst consensus estimate of $2.29 by 11.79 percent. This is a 25700 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $211.79 million which beat the analyst consensus estimate of $117.69 million by 79.95 percent. This is a 213.98 percent increase over sales of $67.45 million the same period last year.

Earnings

Earnings Beats

NUTX

Nutex Health Q1 EPS $2.56 Beats $2.29 Estimate, Sales $211.79M Beat $117.69M Estimate

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 16.42%. Currently, Autodesk has a market capitalization of $63.26 billion. 
Buying $100 In ADSK: If an investor had bought $100 of ADSK stock 15 years ago, it would be worth $985.11 today based on a price of $297.01 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747172715_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ADSK

Here's How Much $100 Invested In Autodesk 15 Years Ago Would Be Worth Today

Gamehost (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GH#TSX">GH</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.24 by 8.33 percent. This is a 18.18 percent increase over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $21.22 million which beat the analyst consensus estimate of $20.50 million by 3.52 percent. This is a 3.15 percent increase over sales of $20.57 million the same period last year.

TSX:GH

Gamehost Q1 GAAP EPS $0.26 Beats $0.24 Estimate, Sales $21.22M Beat $20.50M Estimate

JP Morgan analyst Brian Cheng downgrades ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Overweight to Neutral and lowers the price target from $15 to $8.

Downgrades

ITOS

JP Morgan Downgrades ITeos Therapeutics to Neutral, Lowers Price Target to $8

Offerings

ZONE

CleanCore Solutions Inc: Files For Mixed Shelf Offering Up To $150M

Jones Trading analyst Catherine Novack maintains Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) with a Buy and lowers the price target from $10 to $6.

FEMY

Jones Trading Maintains Buy on Femasys, Lowers Price Target to $6

Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/05/b45393289/nu-holdings-ltd-reports-first-quarter-2025-financial-results"> from the report.&nbsp;</a>
The Details:&nbsp;Nu Holdings&nbsp;reported earnings of 12 cents per share, which missed the consensus estimate of 13 cents. Quarterly revenue came in at $3.2 billion, which missed the Street estimate of $3.23 billion.
Read Next: <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a>
For the first quarter, Nu Holdings reported: 
<ul class="wp-block-list">
<li>4.3 million customers added in the first quarter, driving a 19% year-over-year increase of 19.3 million, reaching a total of 118.6 million customers globally by March 31, 2025.</li>
<li>Monthly Average Revenue per Active Customer (ARPAC) grew 5% sequentially and 17% year-over-year on an FX-neutral basis to $11.2 in Q1. </li>
<li>Monthly Average Cost to Serve Per Active Customer remained below the dollar level, at seven cents per customer, a 4% year-over-year reduction and a decline of 12% sequentially.</li>
<li>Net interest income increased 34% year-over-year and 5% sequentially, reaching a new all-time high of $1.8 billion.</li>
</ul>
&#8220;Starting 2025 strong, Nubank reached 118.6 million customers, adding over four million in a single quarter, showcasing its powerful platform scalability across Brazil, Mexico and Colombia. This growth is driven by deepening customer engagement: 98.7 million monthly active users and an activity rate exceeding 83%. Revenues surged 40% year-over-year (FXN) to $3.2 billion, driven by a 62% expansion in the interest-earning portfolio,&#8221; said David Vélez, CEO of Nubank.
Warren Buffett holds shares of Nu Holdings in Berkshire Hathaway, <a href="https://www.benzinga.com/markets/cryptocurrency/22/05/27208096/warren-buffett-now-owns-bitcoin-heres-how-the-oracle-of-omaha-got-exposure-3" target="_blank" rel="noreferrer noopener">giving him exposure </a>to the company.
NU Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Nu Holdings stock was down 5.71% at $12.39&nbsp;after-hours on Tuesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

After-Hours Center

Movers

Buffett-Backed Nu Holdings Stock Drops After Worse-Than-Expected Q1 Results: Details

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">early-stage breast cancer</a>.
After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) treatment, compared with individuals who received Herceptin, chemotherapy, and placebo.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" target="_blank" rel="noreferrer noopener">Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs</a>
After ten years, <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-05-13" rel="noreferrer noopener">results</a> show:
<ul class="wp-block-list">
<li>91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, p-value=0.044).</li>
<li>A 21% reduction in the risk of death was seen in the prespecified subgroup of people with lymph node-positive disease (HR=0.79).</li>
<li>The previously reported invasive disease-free survival (primary endpoint) benefit was maintained (HR=0.79), strengthening results from earlier APHINITY analyses. No benefit was seen in the node-negative subgroup.</li>
<li>The safety profile, including cardiac safety, was consistent with previous studies, and no new or unexpected safety signals were identified.</li>
</ul>
Full results will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.
In April, Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) and&nbsp;Roche temporarily&nbsp;halted&nbsp;several clinical studies for Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
The company reported a patient death following treatment with Elevidys, having suffered&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
In April, Roche&#8217;s MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous infusion for relapsing multiple sclerosis did not meet its primary endpoint in showing additional benefit in slowing disability progression compared with the currently approved <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613949/why-is-pharma-giant-roche-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Ocrevus IV 600 mg dose</a>.
Price Action: RHHBY stock is trading at $38.34 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45383468/earnings-just-put-dan-loebs-bets-to-the-testheres-what-held-up" target="_blank" rel="noreferrer noopener">Earnings Just Put Dan Loeb&#8217;s Bets To The Test — Here&#8217;s What Held Up</a></li>
</ul>
Photo by OleksSH via Shutterstock

Biotech

Large Cap

Health Care

General

RHHBY

SRPT

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

In today's privacy-led economy, where global regulations are tightening and user expectations are shifting, consent isn't optional, it's strategic. The way your business handles consent can either build trust or quietly erode it.
Usercentrics <a href="http://usercentrics.sjv.io/3JRRWA">Cookiebot CMP</a> doesn't just help you comply with privacy laws. It helps you stay visible in a digital world where data fuels everything from analytics to ad performance. And in an age where Google Consent Mode is mandatory for EU-based tracking, that visibility can make or break your marketing ROI.
<h2 class="wp-block-heading">Privacy Is the New Baseline</h2>
If your website drops cookies or uses online tracking (and 99.9% of them do), you're expected to obtain clear, informed consent from your users. That's not just a GDPR thing. It's also baked into the <a href="https://oag.ca.gov/privacy/ccpa">California Consumer Privacy Act</a> (CCPA/CPRA), <a href="https://iapp.org/resources/article/brazilian-data-protection-law-lgpd-english-translation/">Brazil's LGPD</a>, <a href="https://popia.co.za/">South Africa's POPIA</a>, and the <a href="https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/europe-fit-digital-age/digital-markets-act-ensuring-fair-and-open-digital-markets_en">EU's Digital Markets Act</a> (DMA).
These aren't soft guidelines. They're enforceable laws, and regulators have proven they're willing to act. On top of that, <a href="https://support.google.com/tagmanager/answer/13695607?hl=en">Google's move to enforce Consent Mode for ads and analytics in the EU/EEA that started in March 2024</a> only raises the stakes. If your business relies on data, you'll want to make sure your cookie consent solution is up to par.
<h2 class="wp-block-heading">What Makes Cookiebot CMP Worth It?</h2>
There's a difference between adding a random cookie banner to your homepage and using a Consent Management Platform (CMP) that's designed to scale. Cookiebot CMP isn't just a compliance Band-Aid. It's a <a href="http://usercentrics.sjv.io/3JRRWA">fully integrated system</a> built to scan your site, detect every cookie and tracker, categorize them correctly, and handle user consent in a way that meets both legal and usability standards.
It's used on over 2.3 million websites and apps. It supports over 47 languages and handles more than 7 billion user consents per month. These aren't vanity numbers, they're evidence that Cookiebot CMP is doing the hard work behind the scenes so your business doesn't fall out of step with evolving regulations.
<h2 class="wp-block-heading">Google-Ready by Design</h2>
Google doesn't hand out certifications lightly, but Cookiebot CMP is a Gold Tier certified CMP partner for Google Consent Mode. That means your consent data integrates with Google Ads and Google Analytics. Even if a user denies consent, Google's machine learning models can still generate conversion insights based on modeled data. You don't just avoid penalties, you preserve your performance.
Cookiebot CMP works natively with Google Tag Manager and supports the <a href="https://iabeurope.eu/transparency-consent-framework/">Transparency and Consent Framework (TCF) 2.2</a>, which is a key requirement for any site running programmatic ads in Europe. Bottom line? You don't have to cobble together workarounds to keep your tracking operational and compliant.
<h2 class="wp-block-heading">Built for Real Businesses, Not Just Legal Teams</h2>
One of the common pain points with compliance software is that it's often built either for lawyers or for developers, rarely both. Cookiebot CMP manages to meet in the middle. The interface is intuitive enough for marketers and content managers, but flexible enough for developers who need more control.
It automatically scans your site, detects new cookies as they're added, and keeps your consent banner updated accordingly. You can deploy it with or without a CMS, and it's compatible with various tech stacks. If you want to match your consent banner to your brand, you've got full design control using HTML, CSS, or JavaScript.
And yes, it works across devices, regions, and languages so your visitors in Paris, São Paulo, and San Francisco can each see a localized, legally correct version of your banner. That kind of flexibility isn't just nice to have. It's <a href="http://usercentrics.sjv.io/3JRRWA">a necessity when you're operating in multiple jurisdictions</a> or planning to scale.
<h2 class="wp-block-heading">Your Consent Banner, Your Brand</h2>
Cookiebot CMP gets that user experience matters. A jarring or generic consent banner can send the wrong signal especially when the rest of your site is polished and professional. That's why the platform allows you to fully customize the banner's layout, messaging, and design to reflect your brand.
You can use pre-built templates to get started quickly or go fully custom with your own code. Either way, your cookie consent banner doesn't have to feel like a legal disclaimer slapped on top of a thoughtful brand experience. It can be cohesive, localized, and most importantly transparent.
<h2 class="wp-block-heading">Legal Peace of Mind, Baked In</h2>
Cookiebot CMP comes built with compliance standards for laws like GDPR, the ePrivacy Directive, CCPA/CPRA, LGPD, and POPIA. It also supports the latest version of Google Consent Mode by default. That means less time interpreting legal updates and more time focusing on your business.
With integrations into common ad tech and analytics platforms, including IAB TCF 2.2 and Google's ecosystem, you don't need to worry about whether you're covered. The platform is built to adapt as regulations evolve so you&#8217;re not constantly playing catch-up with each new data law.
<h2 class="wp-block-heading">Easy to Start, Scalable as You Grow</h2>
Cookiebot CMP offers a <a href="http://usercentrics.sjv.io/3JRRWA">14-day free trial</a> so you can see how it works before committing. If your website has fewer than 1000 sessions per month, you can continue using it for free. Once your business expands, plans start at just $8 per month.
You can upgrade at any time, no hidden upsell tricks and you gain access to premium features like multilingual auto-translation, monthly consent reports, full banner customization, and priority support. Whether you're managing one site or twenty, the pricing structure supports your growth instead of penalizing it.
<h2 class="wp-block-heading">Trusted by Global Brands</h2>
This isn't a fly-by-night product cobbled together in a startup garage. Cookiebot CMP is used by global names like Canon, Bauhaus, Pepco, and Orbico: businesses that depend on trust, reputation, and high-performance marketing. That kind of client list says a lot about the platform's reliability, but more importantly, about its adaptability across sectors.
If you're running a B2C e-commerce brand, managing a large corporate website, or simply want peace of mind that your consent data is handled properly, it's worth considering the same CMP these brands rely on.
<h2 class="wp-block-heading">Consent Isn't a Burden, It's a Brand Statement</h2>
Here's the thing most businesses miss: consent isn't just about compliance. It's about showing your users that you respect their data. That you're transparent. That you're worthy of trust. And trust, once earned, pays dividends like longer sessions, higher conversions, better retention.
The real risk isn't overcomplying. It's underestimating how quickly noncompliance can damage your data quality, your ad performance, and your brand. Usercentrics Cookiebot CMP <a href="http://usercentrics.sjv.io/3JRRWA">helps you eliminate that risk</a>, without making it your full-time job.

Tech

Why Usercentrics Cookiebot CMP Is a Must-Have for Privacy-Led Businesses

DA Davidson analyst Rudy Kessinger maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and raises the price target from $415 to $435.

CYBR

DA Davidson Maintains Buy on CyberArk Software, Raises Price Target to $435

K-Bro Linen (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KBL#TSX">KBL</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.28 by 14.29 percent. This is a 5.88 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $90.97 million which beat the analyst consensus estimate of $89.18 million by 2.01 percent. This is a 13.39 percent increase over sales of $80.23 million the same period last year.

TSX:KBL

K-Bro Linen Q1 Adj. EPS $0.32 Beats $0.28 Estimate, Sales $90.97M Beat $89.18M Estimate

PARR

Par Pacific Holdings Files For Mixed Shelf Offering; Size Not Disclosed

CIBC analyst Cosmos Chiu maintains Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) with a Outperformer and lowers the price target from $42 to $39.

PAAS

CIBC Maintains Outperformer on Pan American Silver, Lowers Price Target to $39

CSCI

Cosciens Biopharma Q1 EPS $(1.16) Up From $(4.74) YoY, Sales $1.50M Up From $4.00K YoY

Republic Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) has outperformed the market over the past 15 years by 3.27% on an annualized basis producing an average annual return of 14.96%. Currently, Republic Services has a market capitalization of $74.37 billion. 
Buying $100 In RSG: If an investor had bought $100 of RSG stock 15 years ago, it would be worth $799.97 today based on a price of $237.99 for RSG at the time of writing.
<h3>Republic Services's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747171824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

ClearPoint Neuro Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) reported first-quarter financial results after the market close on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/ac45392053/clearpoint-neuro-reports-first-quarter-2025-results">of the report</a>.
Q1 Earnings: ClearPoint Neuro, a&nbsp;device, cell and gene therapy-enabling company, reported first-quarter revenue of $8.4 million, beating analyst <a href="http://benzinga.com/quote/clpt/earnings">estimates</a> of $8.2 million. The company reported a first-quarter loss of 22 cents per share, missing estimates for a loss of 16 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 11% year-over-year as total consumable product revenue jumped 104%. Here&#8217;s a breakdown of revenue by category:
<ul class="wp-block-list">
<li>Biologics and drug delivery revenue: $4.7 million, up 9%</li>
</ul>
<ul class="wp-block-list">
<li>Neurosurgery navigation and therapy revenue: $3.3 million, up 70%</li>
</ul>
<ul class="wp-block-list">
<li>Capital equipment and software revenue: $500,000, down 63%</li>
</ul>
ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. 
&#8220;Our 2025 fiscal year is off to a strong start as we enter the Fast Forward phase of the company, starting with a record revenue quarter and fueled by multiple new product launches that are delivering on our promise of fast, simple and predictable procedures,&#8221; said Joe Burnett, president and CEO of ClearPoint Neuro. 
&#8220;The foundational investments that we have made over the past few years to grow our global biopharma partnerships, expand navigation into the operating room, and enter the laser therapy market are now paying off and are underlined by&nbsp;104%&nbsp;growth in these single-use devices.&#8221;
Outlook: ClearPoint Neuro affirmed its full-year 2025 sales guidance of $36 million to $41 million versus estimates of $38.23 million. 
ClearPoint executives are currently discussing the quarter on a conference call that kicked off at 4:30 p.m. ET.
CLPT Price Action: <a href="http://benzinga.com/quote/clpt">ClearPoint Neuro shares</a> were up 1.76% after-hours, trading at $14.45 at the time of publication Tueday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45386052/worlds-largest-tobacco-company-is-investing-in-medical-cannabis-heres-what-to-know">World&#8217;s Largest Tobacco Company Is Investing In Medical Cannabis: Here&#8217;s What To Know</a></li>
</ul>
Photo: Shutterstock.

Guidance

CLPT

ClearPoint Neuro Reports Q1 Earnings: Revenue Beat, EPS Miss, Company Affirms FY25 Guidance

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 90 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $10.03 million which beat the analyst consensus estimate of $9.85 million by 1.85 percent. This is a 4.52 percent increase over sales of $9.60 million the same period last year.

Earnings Misses

REED

Reed's Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $10.03M Beat $9.85M Estimate

ALCO

UPDATE: Alico Q2 EPS $(14.58), Sales $17.98M Miss $22.20M Estimate

Wesdome Gold Mines (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WDOFF#OTC">WDOFF</a>) reported quarterly earnings of $0.29 per share. This is a 480 percent increase over earnings of $0.05 per share from the same period last year. The company reported $130.70 million in sales this quarter. This is a 74.55 percent increase over sales of $74.88 million the same period last year.

WDOFF

Wesdome Gold Mines Q1 Adj. EPS $0.29 Up From $0.05 YoY, Sales $130.70M Up From $74.88M YoY

Press Releases

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Comments

PureTech Health

PureTech Health (PRTC) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL